Compositions and methods for treatment of vaginal infections
Inventors
Faulkner, Mark C. • Seymour, Deeannah
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12109195-B2
Publication Date
2024-10-08
Expiration Date
Abstract
Compositions and methods for treatment and prevention of vaginal infections where the compositions include creatinine, such as protonated creatinine or creatinine salts, and optionally one or more weak acids, such as boric acid. The compositions may be used to treat and/or prevent a vaginal infection, such as bacterial vaginosis, to prevent recurrence of a vaginal infection, to treat and/or prevent a sexually transmitted disease (STD) or sexually transmitted infection (STI), and reduce the incidence and/or risk of a subject transmitting a STI or STD.
Core Innovation
The invention provides compositions and methods that inhibit growth of one or more species of bacteria associated with bacterial vaginosis by using protonated creatinine and/or a protonated creatinine salt. The composition contains the protonated creatinine, protonated creatinine salt, or combinations thereof in an amount of about 10 mg to about 300 mg, and the bacteria are subjected to the composition to achieve growth inhibition.
For killing rather than merely inhibiting, the invention includes compositions that further comprise a weak acid together with the protonated creatinine and/or protonated creatinine salt. The composition contains the protonated creatinine, protonated creatinine salt, or combination in an amount of about 10 mg to about 300 mg, and the weak acid in an amount of about 500 mg to about 700 mg, and the bacteria associated with bacterial vaginosis are subjected to the composition.
The invention additionally includes compositions for inhibiting growth of Gardnerella vaginalis, Mobiluncus mulieris, or combinations thereof, where the composition comprises protonated creatinine and/or a protonated creatinine salt, a weak acid, and a probiotic and/or a prebiotic. In this embodiment, the protonated creatinine component is present in an amount of about 10 mg to about 300 mg, and the weak acid is present in an amount of about 500 mg to about 700 mg.
Claims Coverage
The partial content includes three independent claims, each centered on preparing a vaginal-related composition and subjecting one or more bacterial species associated with bacterial vaginosis to that composition. Across the independent claims, the main inventive features involve protonated creatinine and/or protonated creatinine salt, weak acid co-formulation, and probiotic/prebiotic inclusion.
Protonated creatinine composition for inhibiting BV-associated bacterial growth
A method for inhibiting growth of one or more species of bacteria associated with bacterial vaginosis by preparing a composition consisting of protonated creatinine, a protonated creatinine salt, or combinations thereof present in an amount of about 10 mg to about 300 mg, and subjecting the one or more species of bacteria to the composition.
Protonated creatinine plus weak acid composition for killing BV-associated bacteria
A method for killing one or more species of bacteria associated with bacterial vaginosis by preparing a composition consisting of protonated creatinine, a protonated creatinine salt, or combinations thereof, and a weak acid, wherein the protonated creatinine, protonated creatinine salt, or combination is present in an amount of about 10 mg to about 300 mg and the weak acid is present in an amount of about 500 mg to about 700 mg, and subjecting the one or more species of bacteria to the composition.
Protonated creatinine plus weak acid plus probiotic/prebiotic for inhibiting Gardnerella/Mobiluncus growth
A method for inhibiting growth of Gardnerella vaginalis, Mobiluncus mulieris, or a combination thereof by preparing a composition consisting of a protonated creatinine, a protonated creatinine salt, or combinations thereof, a weak acid, and a probiotic, prebiotic, or combinations thereof, wherein the protonated creatinine, protonated creatinine salt, or combination is present in an amount of about 10 mg to about 300 mg and the weak acid is present in an amount of about 500 mg to about 700 mg, and subjecting the Gardnerella vaginalis, Mobiluncus mulieris, or a combination thereof to the composition.
Across the independent claims, the core claim coverage is directed to growth inhibition using a composition containing protonated creatinine and/or a protonated creatinine salt in about 10 mg to about 300 mg, killing using the same protonated creatinine component combined with a weak acid in about 500 mg to about 700 mg, and multi-component growth inhibition for Gardnerella vaginalis and/or Mobiluncus mulieris using protonated creatinine plus weak acid plus probiotic and/or prebiotic.
Stated Advantages
Inhibits growth of one or more species of bacteria associated with bacterial vaginosis.
Kills one or more species of bacteria associated with bacterial vaginosis.
Inhibits growth of Gardnerella vaginalis and/or Mobiluncus mulieris.
Documented Applications
Treating or preventing vaginal infections associated with bacterial vaginosis, including by inhibiting growth of BV-associated bacteria and by killing BV-associated bacterial species.
Reducing incidence or risk of transmission of STIs/STDs as described in the provided partial content.
Using compositions intended for vaginal infection settings including bacterial vaginosis via pH lowering and antibacterial activity, as described in the provided partial content.
Interested in licensing this patent?